Clinical trial · Observational
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
Predictors of Health-Related Quality of Life in Adults With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT07030400CI-TRIAL-00107004recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia | ALIAS | 0.90 |
| Small Lymphocytic Lymphoma (SLL) | Small Lymphocytic Lymphoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| B-Cell Lymphoma 2 Protein Inhibitor | Drug | — | UNRESOLVED |
| Bruton's tyrosine kinase inhibitor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Bruton's tyrosine kinase inhibitor treatment
- description
- Patients treated with a Bruton's tyrosine kinase inhibitor.
- interventionNames
- Drug: Bruton's tyrosine kinase inhibitor
- label
- B-Cell Lymphoma 2 Protein Inhibitor treatment
- description
- Patients treated with a B-Cell Lymphoma 2 Protein Inhibitor.
- interventionNames
- Drug: B-Cell Lymphoma 2 Protein Inhibitor
Primary outcomes (3)
- measure
- Health Related Quality of Life (HRQOL)
- timeFrame
- Up to 2 years
- description
- Compare the differences in HRQOL scores measured by the Functional Assessment of Cancer Therapy Leukemia version for patients receiving BTKi, and BCL2i within 7 days of beginning treatment and at days 30,60, 90, 180, 1 year, 1.5 years, and 2 years following initiation of treatment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +/- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included. * Subjects must be able to read and speak English or Spanish at the 8th grade level. Exclusion Criteria: * Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.
References
Publications (0)
Data not yet available
No reference posted for this study.